Gilead’s $3B Tubulis takeout to add ADC depth beyond Trodelvy

Gilead’s $3 billion-plus acquisition of German start-up Tubulis will add more products and a platform to what had been a barren pipeline of ADCs behind anchor therapy Trodelvy.

The Tubulis GmbH takeout marks the fourth multi-billion-dollar biotech acquisition in a week, extending a brisk 2026 M&A run that has been concentrated in cancer, metabolic disease, neurology and the immunology and inflammatory disease area...